A new editorial was recently published in Oncotarget’s Volume 15, on July 10, 2024, entitled, “The advances in targeting CD47/SIRPα “do not eat me” axis and their ongoing challenges as an anticancer therapy.”
FDA lifts clinical hold on Mersana’s STING agonist, PhI starting dose lowered after patient death
The FDA has lifted the full clinical hold on Mersana Therapeutics’ STING-targeted antibody-drug conjugate on the back of the company making Phase I study dosing
November 1, 2023